Entecavir and Abraxane drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Entecavir (entecavir) and Abraxane (paclitaxel). Common drug interactions include pancytopenia among females and abdominal distension among males.

The phase IV clinical study analyzes what interactions people have when they take Entecavir and Abraxane. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Entecavir?

Entecavir has active ingredients of entecavir. It is often used in hepatitis b. eHealthMe is studying from 7,354 Entecavir users. Check the latest studies of Entecavir.

What is Abraxane?

Abraxane has active ingredients of paclitaxel. It is often used in breast cancer metastatic. eHealthMe is studying from 19,196 Abraxane users. Check the latest studies of Abraxane.

On Aug, 01, 2026

11 people who take Entecavir and Abraxane together, and have interactions are studied.

Entecavir and Abraxane drug interactions.

What are the common drug interactions of Entecavir and Abraxane, by gender? *:

female:

Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Pyrexia (fever)
Sepsis (a severe blood infection that can lead to organ failure and death)
Vascular neoplasm (tumour of vascular origin)
Vomiting
Alopecia (absence of hair from areas of the body)
Aphthous ulcer (mouth ulcer)
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Hypersensitivity

male:

Abdominal distension
Pericardial effusion (fluid around the heart)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)

What are the common drug interactions of Entecavir and Abraxane, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Abdominal distension
Pericardial effusion (fluid around the heart)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)

60+:

Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Abdominal pain upper
Aphthous ulcer (mouth ulcer)
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Hypersensitivity
Leukopenia (less number of white blood cells in blood)
Nausea (feeling of having an urge to vomit)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Cholecystitis acute (rapid infection of gallbladder)

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 4 people, 36.36%
Type 2 Diabetes: 3 people, 27.27%
Bronchial Carcinoma (lung cancer): 2 people, 18.18%
Chest Pain: 2 people, 18.18%
Chronic Hepatitis (long lasting inflammation of liver): 2 people, 18.18%
Hepatitis B Antibody Positive: 2 people, 18.18%
Anaemia (lack of blood): 2 people, 18.18%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 9.09%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 9.09%
Oesophageal Cancer Metastatic (cancer of oesophagues spreads to other part): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Entecavir and Abraxane?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously